Radiopharm Theranostics: Developing Innovative Radiopharmaceuticals for a Highly Underserved Oncology Sector
Radiopharm Theranostics (ASX:RAD) is a biopharmaceutical company that develops radiopharmaceutical products for diagnostic and therapeutic applications. With four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb), Radiopharm aims to commercialize its pipeline for possible licensing and distribution agreements seeking to develop for the diagnosis and treatment of certain cancers.
Radiopharm Theranostics represents a promising investment opportunity in the rapidly growing field of radiopharmaceuticals, leveraging its innovative technology platform and diverse clinical pipeline.
Radiopharm’s clinical stage development in the pipeline include:
PD-L1 (non-small cell lung cancer indication) – currently in phase 1 in Australia;HER2 (breast/gastric cancer indication) – will begin phase 1 trials this year;Integrin VB6 (pancreatic cancer indication) – now in Phase I imaging in pancreatic cancer.Fatty Acid Synthase (brain METS indication) – preclinical has been completed and with IND approval for Phase IIb Imaging
Company Highlights
Radiopharm Theranostics is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology.Radiopharm has four licensed platform technologies – nanobody, peptide, small molecules and monoclonal antibodies (mAb) – with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.The company has received clearance from the US Food and Drug Administration for an investigational new drug application with two INDs (one for RAD 301 and one for RAD 101). Phase 1 for RAD 301 and for RAD 204 is in progress.The company aims to commercialize its pipeline for possible licensing and distribution agreements and has secured four platform technologies, which it is seeking to develop for the diagnosis and treatment of certain cancers.
This Radiopharm Theranostics profile is part of a paid investor education campaign.*
Click here to connect with Radiopharm Theranostics (ASX:RAD) to receive an Investor Presentation